On September 4, JD HEALTH rose 3.44% in regular trading, trading at HK$37.24/share, with turnover of approximately HK$73.01 million.

The rally was driven by a flurry of strategic cooperation agreements signed in recent days. On September 3, JD HEALTH signed a strategic cooperation agreement with Jointown Pharmaceutical, under which the two parties will deepen collaboration across supply chain, fulfillment, consumer scenarios, and digital procurement, with first-half cooperation scale growing 32% year over year. On September 2, the company partnered with Likang Life Sciences to advance personalized mRNA tumor vaccine and precision immunotherapy initiatives. On the same day, its subsidiary Langjianwei Hospital signed a strategic cooperation framework agreement with Gobroad Medical Group.

These partnerships come on the heels of a strong first-half performance. JD HEALTH reported H1 revenue of RMB 40.9 billion, up 15.9% year over year, with Non-IFRS operating profit of RMB 3.5 billion, up 40.3%. Gross margin improved from 25.2% to 26.1%. CICC maintained its Outperform rating with a target price of HK$66.2, citing profit output trending above expectations.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)